JP2017525776A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525776A5
JP2017525776A5 JP2017530425A JP2017530425A JP2017525776A5 JP 2017525776 A5 JP2017525776 A5 JP 2017525776A5 JP 2017530425 A JP2017530425 A JP 2017530425A JP 2017530425 A JP2017530425 A JP 2017530425A JP 2017525776 A5 JP2017525776 A5 JP 2017525776A5
Authority
JP
Japan
Prior art keywords
disorder
disease
dementia
pharmaceutical composition
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017530425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525776A (ja
JP6430015B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/069601 external-priority patent/WO2016030444A1/en
Publication of JP2017525776A publication Critical patent/JP2017525776A/ja
Publication of JP2017525776A5 publication Critical patent/JP2017525776A5/ja
Application granted granted Critical
Publication of JP6430015B2 publication Critical patent/JP6430015B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017530425A 2014-08-27 2015-08-27 新規クロモンオキシム誘導体、および代謝型グルタミン酸受容体のアロステリックモジュレーターとしてのそれの使用 Expired - Fee Related JP6430015B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182468.0 2014-08-27
EP14182468 2014-08-27
PCT/EP2015/069601 WO2016030444A1 (en) 2014-08-27 2015-08-27 Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors

Publications (3)

Publication Number Publication Date
JP2017525776A JP2017525776A (ja) 2017-09-07
JP2017525776A5 true JP2017525776A5 (https=) 2017-10-19
JP6430015B2 JP6430015B2 (ja) 2018-11-28

Family

ID=51421865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017530425A Expired - Fee Related JP6430015B2 (ja) 2014-08-27 2015-08-27 新規クロモンオキシム誘導体、および代謝型グルタミン酸受容体のアロステリックモジュレーターとしてのそれの使用

Country Status (26)

Country Link
US (3) US10017521B2 (https=)
EP (3) EP3186257B1 (https=)
JP (1) JP6430015B2 (https=)
KR (1) KR101870589B1 (https=)
CN (2) CN110343118A (https=)
AU (1) AU2015308438B2 (https=)
CA (1) CA2956191C (https=)
CY (1) CY1121352T1 (https=)
DK (1) DK3186257T3 (https=)
ES (1) ES2714073T3 (https=)
HR (1) HRP20190343T1 (https=)
HU (1) HUE041941T2 (https=)
IL (1) IL250287B (https=)
LT (1) LT3186257T (https=)
MA (3) MA40530A (https=)
ME (1) ME03339B (https=)
MX (1) MX369643B (https=)
NZ (1) NZ728853A (https=)
PL (1) PL3186257T3 (https=)
PT (1) PT3186257T (https=)
RS (1) RS58592B1 (https=)
RU (1) RU2672569C2 (https=)
SI (1) SI3186257T1 (https=)
SM (1) SMT201900152T1 (https=)
TR (1) TR201903332T4 (https=)
WO (1) WO2016030444A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3186257T (lt) * 2014-08-27 2019-04-25 Prexton Therapeutics Sa Nauji chromono oksimo dariniai ir jų panaudojimas kaip metabotropinių gliutamato receptorių alosterinių moduliatorių
RU2018110580A (ru) 2015-08-27 2019-09-30 Прекстон Терапьютикс Са Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
US20220089609A1 (en) 2018-07-26 2022-03-24 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065467A (en) 1973-12-27 1977-12-27 Carlo Erba, S. P. A. 5:6-Benzo δ-pyrone derivatives and process for their preparation
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
JP3993651B2 (ja) * 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
EP1298129A3 (en) 2001-09-28 2003-06-04 Central Glass Company, Limited Process for producing 4-sustituted benzopyran derivatives
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
WO2004092154A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20070027216A1 (en) 2005-07-15 2007-02-01 Bridget Larson Novel hydrochloride salts of levodopa
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
US20100144756A1 (en) 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
CN102812014B (zh) * 2009-10-30 2016-01-20 多美恩医疗公司 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途
CN106883246B (zh) * 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
US20140349994A1 (en) * 2012-01-18 2014-11-27 Addex Pharma S.A. Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors
LT3186257T (lt) * 2014-08-27 2019-04-25 Prexton Therapeutics Sa Nauji chromono oksimo dariniai ir jų panaudojimas kaip metabotropinių gliutamato receptorių alosterinių moduliatorių
RU2018110580A (ru) 2015-08-27 2019-09-30 Прекстон Терапьютикс Са Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии

Similar Documents

Publication Publication Date Title
JP2019524822A5 (https=)
JP2016535786A5 (https=)
EP3043785B1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
JOP20230235A1 (ar) عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون
JP2016199576A5 (https=)
RU2009126742A (ru) Композиции и способы применения (r)-прамипексола
JP2016528301A5 (https=)
JP2013526544A5 (https=)
HRP20191055T1 (hr) Terapeutska sredstva za neurodegenerativne bolesti
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
NZ700374A (en) New therapeutic approaches for treating parkinson’s disease
EA200800430A1 (ru) Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов
JP2018507886A5 (https=)
JP2012523430A5 (https=)
JP2017525776A5 (https=)
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
JP2016509030A5 (https=)
PH12018500430A1 (en) Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
AR112683A1 (es) Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende
HRP20210361T1 (hr) Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
JP2018502163A5 (https=)